Alere rapid diagnostics revenues were $548 million in the quarter, driven by infectious disease and cardiometabolic testing product sales.
Abbott said that the Japanese Red Cross Society selected it as the exclusive supplier of blood and plasma screening serological instrumentation, tests, and consumables.
The company will provide 1 million rapid diagnostic tests, $750,000, and technical expertise as part of an effort in Odisha to eliminate the disease.
Abbott CEO Miles White is bullish on the firm's Alinity systems, while Quest and LabCorp see acquisitions as the likely result of further PAMA-related cuts.
A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.
A court in San Diego has stated that part of the suit between Quidel and Beckman is void as a matter of law.
Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.
The FDA cleared LabCorp's assay for quantitative determination of total cholesterol, high density lipoprotein cholesterol, triglycerides, and apolipoprotein B.
Abbott said that the next-generation molecular POC assays have also been CLIA waived for use on the Abbott ID NOW instrument, formerly called Alere i.